Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

Epilepsia

Volumn 56, Issue 8, 2015, Pages 1246-1251

  Geffrey, Alexandra L ^a   Pollack, Sarah F ^a   Bruno, Patricia L ^a   Thiele, Elizabeth A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Cannabis; Cytochrome P450 pathway; Norclobazam; Treatment resistant epilepsy

Indexed keywords

CANNABIDIOL; CLOBAZAM; CYTOCHROME P450; ETIRACETAM; FELBAMATE; HARKOSERIDE; LAMOTRIGINE; NORCLOBAZAM; PHENYTOIN; RUFINAMIDE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; BENZODIAZEPINE DERIVATIVE; N-DESMETHYLCLOBAZAM;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; ATAXIA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG RESISTANT EPILEPSY; DRUG SAFETY; FEMALE; HUMAN; LOSS OF APPETITE; MALE; PATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTLESSNESS; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; TREATMENT RESPONSE; TREMOR; URINE RETENTION; YOUNG ADULT; DRUG INTERACTION; EPILEPSY; METABOLISM;

ADOLESCENT; BENZODIAZEPINES; CANNABIDIOL; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; YOUNG ADULT;

EID: 84938748697     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.13060     Document Type: Article

References (24)

1. Porter BE, Jacobson C,. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Presented at the NIH Annual Curing the Epilepsies Conference, Washington, DC, 2013.
2. Izquierdo I, Tannhauser M,. Letter: The effect of cannabidiol on maximal electroshock seizures in rats. J Pharm Pharmacol 1973; 25: 916-917.
3. Chesher GB, Jackson DM,. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia 1974; 37: 255-264.
4. Chesher GB, Jackson DM, Malor RM,. Interaction of delta9-tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions. J Pharm Pharmacol 1975; 27: 608-609.
5. Consroe PF, Wolkin AL,. Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977; 29: 500-501.
6. Turkanis SA, Smiley KA, Borys HK, et al., An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats. Epilepsia 1979; 20: 351-363.
7. Consroe P, Benedito MA, Leite JR, et al., Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982; 83: 293-298.
8. Jones NA, Hill AJ, Smith I, et al., Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010; 332: 569-577.
9. Jones NA, Glyn SE, Akiyama S, et al., Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012; 21: 344-352.
10. Cunha JM, Carlini EA, Pereira AE, et al., Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175-185.
11. Gloss D, Vickrey B,. (2012) Cannabinoids for epilepsy. Cochrane Database Syst Rev 6: CD009270.
12. Lundbeck. Clinical pharmacology and clinical studies. Clobazam Full Prescribing Information, 2013.
13. Jiang R, Yamaori S, Takeda S, et al., Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011; 89: 165-170.
14. Yamaori S, Ebisawa J, Okushima Y, et al., Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011; 88: 730-736.
15. Jiang R, Yamaori S, Okamoto Y, et al., Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet 2013; 28: 332-338.
16. Naccarato M, Yoong D, Kovacs C, et al., A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther 2012; 17: 589-592.
17. Giraud C, Tran A, Rey E, et al., In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004; 32: 1279-1286.
18. Bergamaschi MM, Queiroz RH, Zuardi AW, et al., Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011; 6: 237-249.
19. Yamamoto Y, Takahashi Y, Imai K, et al., Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19. Epilepsy Behav 2014; 34: 124-126.
20. Tran A, Rey E, Pons G, et al., Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997; 62: 490-504.
21. Wen X, Wang JS, Kivisto KT, et al., In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001; 52: 547-553.
22. Yamamoto Y, Takahashi Y, Imai K, et al., Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy. Eur J Clin Pharmacol 2014; 70: 1203-1210.
23. Walzer M, Bekersky I, Blum RA, et al., Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 2012; 32: 340-353.
24. Desta Z, Zhao X, Shin JG, et al., Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-958.